AeroVironment (AVAV) is seeing notable premarket action, potentially driven by its strong revenue growth, with a reported $2.0 billion in revenue for FY26, a significant 140.9% year-over-year increase. Despite this top-line expansion, the company faces profitability challenges, evidenced by a negative net margin of -13.4% and diluted EPS of $-5.40.

Merck (MRK) is also on the move, with its established pharmaceutical business reporting $65.0 billion in revenue for FY25, growing at a more modest 1.3% YoY. Merck maintains a robust net margin of 28.1% and a diluted EPS of $7.28, reflecting its mature and profitable operations.

The premarket buzz suggests investors are reacting to either specific company news, analyst upgrades/downgrades, or broader sector trends impacting these companies. For AVAV, the focus is likely on balancing rapid growth with achieving profitability, while for MRK, it's about sustaining growth and pipeline developments in a competitive pharmaceutical landscape.